Merck and Moderna's melanoma drug combo beats Keytruda alone in trial

August 19, 2026 6:45 AM

Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced that their Phase 3 INTerpath-001 trial of intismeran autogene in combination with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found